T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1245-1251

  Wang, Zhen ^a,b   Li, Xing Min ^c   Shang, Kun ^a,b   Zhang, Peng ^b   Wang, Chao Fu ^a,b   Xin, Yu Hu ^a,b   Zhou, Lu ^b   Li, Ying Yi ^a,b,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Cancer Research Institute ^*  (China)

^d Cancer Res Inst   (Japan)

Author keywords

Anticancer drug; Apoptosis; Pim kinase; Stemonamide synthetic intermediate

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHOTRANSFERASE; PROTEIN BAD; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 3; SERINE; STEMONAMIDE SYNTHETIC INTERMEDIATE; T 18; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SPIRO COMPOUNDS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872812183     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2233     Document Type: Article

References (61)

1. Aune D, Vieira AR, Chan DS, et al: Height and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies. Cancer Causes Control 23: 1213-1222, 2012.
2. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004. (Pubitemid 38410779)
3. Hochster HS, Haller DG, de Gramont A, et al: Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107: 676 - 685, 2006. (Pubitemid 44232660)
4. Mikkers H, Allen J, Knipscheer P, et al: High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32: 153-159, 2002. (Pubitemid 34977211)
5. Qian KC, Wang L, Hickey ER, et al: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130-6137, 2005. (Pubitemid 40280098)
6. Kumar A, Mandiyan V, Suzuki Y, et al: Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 348: 183-193, 2005. (Pubitemid 40461849)
7. Holder S, Zemskova M, Zhang C, et al: Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6: 163-172, 2007. (Pubitemid 46206679)
8. Alvarado Y, Giles FJ and Swords RT: The PIM kinases in hematological cancers. Expert Rev Hematol 5: 81-96, 2012.
9. Kim KT, Baird K, Ahn JY, et al: Pim-1 is up-regulated by consti-tutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759-1767, 2005. (Pubitemid 40223700)
10. Pasqualucci L, Neumeister P, Goossens T, et al: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341-346, 2001. (Pubitemid 32691848)
11. Gaidano G, Pasqualucci L, Capello D, et al: Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102: 1833-1841, 2003. (Pubitemid 37022580)
12. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001. (Pubitemid 32801464)
13. Valdman A, Fang X, Pang ST, Ekman P and Egevad L: Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367-371, 2004. (Pubitemid 39050657)
14. Xu Y, Zhang T, Tang H, et al: Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol 92: 326-330, 2005. (Pubitemid 41779291)
15. Liu LM, Zhang JX, Wang XP, Guo HX, Deng H and Luo J: Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats. Eur J Clin Invest 40: 127-138, 2010.
16. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C and Mukaida N: Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 66: 6741-6747, 2006. (Pubitemid 44085632)
17. Popivanova BK, Li Y Y, Zheng H, et al: Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 98: 321-328, 2007. (Pubitemid 46195601)
18. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ and Kraft A: The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 18: 4022-4031, 1999. (Pubitemid 29361341)
19. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17: 1841-1854, 2003. (Pubitemid 36944562)
20. Yan B, Zemskova M, Holder S, et al: The PIM-2 kinase phos-phorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278: 45358-45367, 2003. (Pubitemid 37432672)
21. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ and Arthur JS: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 7: 1, 2006.
22. Brault L, Gasser C, Bracher F, Huber K, Knapp S and Schwaller J: PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004-1015, 2010.
23. Anizon F, Shtil AA, Danilenko VN and Moreau P: Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. Curr Med Chem 17: 4114-4133, 2010.
24. Akue-Gedu R, Rossignol E, Azzaro S, et al: Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 52: 6369-6381, 2009.
25. Tao ZF, Hasvold LA, Leverson JD, et al: Discovery of 3H-benzo[4,5] thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human proto-oncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem 52: 6621-6636, 2009.
26. Chen LS, Redkar S, Bearss D, Wierda WG and Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lympho-cytic leukemia cells. Blood 114: 4150-4157, 2009.
27. Mumenthaler SM, Ng PY, Hodge A, et al: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8: 2882-2893, 2009.
28. Yano T, Ishikura H, Kato H, Ogawa Y, Kondo S and Yoshiki T: Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients. Jpn J Cancer Res 92: 83-87, 2001. (Pubitemid 32175482)
29. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M and Todaro G: Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747, 1975.
30. Yunis AA, Arimura GK and Russin DJ: Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 128-135, 1977. (Pubitemid 8016933)
31. Leibovitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC and Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569, 1976.
32. Bruns CJ, Harbison MT, Kuniyasu H, Eue I and Fidler IJ: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1: 50-62, 1999.
33. Marshall CJ, Franks LM and Carbonell AW: Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 58: 1743-1751, 1977. (Pubitemid 8118752)
34. Brattain MG, Brattain DE, Fine WD, et al: Initiation and characterization of cultures of human colonic carcinoma with different biological characteristics utilizing feeder layers of confluent fibroblasts. Oncodev Biol Med 2: 355-366, 1981. (Pubitemid 12163670)
35. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980.
36. Nakabayashi H, Taketa K, Miyano K, Yamane T and Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863, 1982. (Pubitemid 12054507)
37. Taniguchi T, Tanabe G, Muraoka O and Ishibashi H: Total synthesis of (+/-)-stemonamide and (+/-)-isostemonamide using a radical cascade. Org Lett 10: 197-199, 2008.
38. Li Y Y, Wang Y Y, Taniguchi T, et al: Identification of stemon-amide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability. Int J Cancer 127: 474-484, 2010.
39. Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H and Mukaida N: Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity. Cancer Sci 103: 107-115, 2011.
40. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005. (Pubitemid 41434384)
41. Rhodes N, Heerding DA, Duckett DR, et al: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68: 2366-2374, 2008. (Pubitemid 351521811)
42. André T, Balosso J, Louvet C, et al: Adenocarcinoma of the pancreas. General characteristics. Presse Med 27: 533-536, 1998 (In French).
43. Jian J, Hu ZF and Huang Y: Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1. Ai Zheng 28: 461-465, 2009 (In Chinese).
44. Fujii C, Nakamoto Y, Lu P, et al: Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 114: 209-218, 2005. (Pubitemid 40194286)
45. Zheng HC, Tsuneyama K, Takahashi H, et al: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol 134: 481-488, 2008. (Pubitemid 351322384)
46. Bullock AN, Debreczeni J, Amos AL, Knapp S and Turk BE: Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280: 41675-41682, 2005. (Pubitemid 43000572)
47. Bullock AN, Russo S, Amos A, et al: Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One 4: e7112, 2009.
48. Swords R, Kelly K, Carew J, et al: The Pim kinases: new targets for drug development. Curr Drug Targets 12: 2059-2066, 2011.
49. Pogacic V, Bullock AN, Fedorov O, et al: Structural analysis identifes imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 67: 6916-6924, 2007. (Pubitemid 47105539)
50. Dakin LA, Block MH, Chen H, et al: Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 22: 4599-4604, 2012.
51. Xia Z, Knaak C, Ma J, et al: Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52: 74-86, 2009.
52. Lin YW, Beharry ZM, Hill EG, et al: A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115: 824-833, 2010.
53. Nishiguchi GA, Atallah G, Bellamacina C, et al: Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 21: 6366-6369, 2011.
54. Gavara L, Saugues E, Alves G, Debiton E, Anizon F and Moreau P: Synthesis and biological activities of pyrazolo[3,4-g] quinoxaline derivatives. Eur J Med Chem 45: 5520-5526, 2010.
55. Akue-Gedu R, Letribot B, Saugues E, Debiton E, Anizon F and Moreau P: Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives. Bioorg Med Chem Lett 22: 3807-3809, 2012.
56. Akue-Gedu R, Nauton L, Thery V, et al: Synthesis, Pim kinase inhibitory potencies and in vitro antiproliferative activities of diversely substituted pyrrolo[2,3-a]carbazoles. Bioorg Med Chem 18: 6865-6873, 2010.
57. Letribot B, Akue-Gedu R, Santio NM, et al: Use of copper(I) catalyzed azide alkyne cycloaddition (CuAAC) for the preparation of conjugated pyrrolo[2,3-a]carbazole Pim kinase inhibitors. Eur J Med Chem 50: 304-310, 2012.
58. Chen WS, Xu PZ, Gottlob K, et al: Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15: 2203-2208, 2001. (Pubitemid 32843832)
59. Easton RM, Cho H, Roovers K, et al: Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25: 1869-1878, 2005. (Pubitemid 40280150)
60. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M and Brass LF: Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 113: 441-450, 2004. (Pubitemid 38544188)
61. Mukaida N, Wang YY and Li YY: Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci 102: 1437-1442, 2011.